Tri Locum Partners LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Tri Locum Partners LP reported 19 stock positions worth $813.2 million. Its top holding was Johnson & Johnson (JNJ) at 13.3% of the portfolio, followed by Vertex Pharmaceuticals (VRTX, 12.3%) and Eli Lilly (LLY, 11.3%). Compared with Q1 2026, it opened 4 new positions, sold out of 2, added to 9 and reduced 6. The biggest buy was a new position in Enliven Therapeutics (ELVN) and the biggest sale an exit from Thermo Fisher Scientific (TMO).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001826434
- Portfolio Value
- $813.2M (Q2 2026)
- SEC Filing
- 0001826434-26-000005 ↗ filed Aug 14, 2026
Holdings Value
Holdings 19 stocks · $813.2M
| JNJ Johnson & Johnson | 13.27% | 424,945 | $107.9M | Add +2.5% |
| VRTX Vertex Pharmaceuticals Inc. | 12.33% | 201,791 | $100.2M | Add +56.0% |
| LLY Eli Lilly & Co. | 11.29% | 76,532 | $91.8M | Add +23.9% |
| ASND Ascendis Pharma A/S | 8.49% | 258,740 | $69.0M | Add +1.3% |
| DXCM Dexcom Inc. | 6.80% | 820,479 | $55.3M | Add +17.5% |
| AXSM Axsome Therapeutics Inc. | 6.60% | 219,308 | $53.7M | Add +253.1% |
| JAZZ Jazz Pharmaceuticals PLC | 6.57% | 221,720 | $53.4M | Add +39.7% |
| ELVN Enliven Therapeutics Inc. | 5.41% | 866,716 | $44.0M | New |
| ARGX Argenx SE - ADR | 4.75% | 41,596 | $38.6M | Add +31.5% |
| MDGL Madrigal Pharmaceuticals Inc. | 4.51% | 68,273 | $36.7M | Reduce -33.9% |
| RVMD Revolution Medicines Inc. | 3.50% | 151,822 | $28.4M | New |
| UTHR United Therapeutics Corp. | 3.13% | 47,026 | $25.5M | Reduce -33.2% |
| TEVA Teva Pharmaceutical-SP ADR | 3.11% | 746,835 | $25.3M | Reduce -26.9% |
| TARS Tarsus Pharmaceuticals Inc. | 2.54% | 328,340 | $20.7M | Add +30.0% |
| ISRG Intuitive Surgical Inc. | 2.35% | 47,983 | $19.1M | Reduce -68.7% |
| CYTK Cytokinetics Inc. | 2.03% | 194,000 | $16.5M | New |
| DNTH Dianthus Therapeutics Inc. | 1.45% | 120,712 | $11.8M | Reduce -17.1% |
| BBNX Beta Bionics Inc. | 0.95% | 493,344 | $7.7M | New |
| DFTX Definium Therapeutics Inc. | 0.94% | 162,996 | $7.7M | Reduce -55.9% |
Portfolio Sells Q1 2026 → Q2 2026
| TMO Thermo Fisher Scientific Inc. | Sold out | 0.00% | −9.13 |
| ISRG Intuitive Surgical Inc. | Reduce -68.7% | 2.35% | −7.57 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −4.44 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -33.9% | 4.51% | −3.08 |
| UTHR United Therapeutics Corp. | Reduce -33.2% | 3.13% | −2.72 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -26.9% | 3.11% | −1.20 |
| DNTH Dianthus Therapeutics Inc. | Reduce -17.1% | 1.45% | −0.27 |
| DFTX Definium Therapeutics Inc. | Reduce -55.9% | 0.94% | −0.04 |
Portfolio Buys Q1 2026 → Q2 2026
| ELVN Enliven Therapeutics Inc. | New | 5.41% | +5.41 |
| AXSM Axsome Therapeutics Inc. | Add +253.1% | 6.60% | +5.13 |
| VRTX Vertex Pharmaceuticals Inc. | Add +56.0% | 12.33% | +4.22 |
| RVMD Revolution Medicines Inc. | New | 3.50% | +3.50 |
| LLY Eli Lilly & Co. | Add +23.9% | 11.29% | +3.31 |
| JAZZ Jazz Pharmaceuticals PLC | Add +39.7% | 6.57% | +2.36 |
| CYTK Cytokinetics Inc. | New | 2.03% | +2.03 |
| ARGX Argenx SE - ADR | Add +31.5% | 4.75% | +1.50 |
| BBNX Beta Bionics Inc. | New | 0.95% | +0.95 |
| DXCM Dexcom Inc. | Add +17.5% | 6.80% | +0.64 |
| ASND Ascendis Pharma A/S | Add +1.3% | 8.49% | +0.29 |
| TARS Tarsus Pharmaceuticals Inc. | Add +30.0% | 2.54% | +0.05 |
| JNJ Johnson & Johnson | Add +2.5% | 13.27% | −0.95 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $813.2M | JNJ, VRTX, LLY, ASND, DXCM |
| Q1 2026 | 17 | $712.5M | JNJ, ISRG, TMO, ASND, VRTX |
| Q4 2025 | 15 | $770.1M | JNJ, DHR, LLY, UTHR, ASND |
| Q3 2025 | 18 | $435.1M | JNJ, UTHR, MRK, AXSM, ASND |
| Q2 2025 | 23 | $329.5M | TEVA, MDGL, ALNY, ARGX, ASND |
| Q1 2025 | 22 | $194.9M | CI, MCK, SLNO, TEVA, INSP |
| Q4 2024 | 28 | $482.7M | TEVA, ZBH, ARGX, NTRA, INSP |
| Q3 2024 | 20 | $417.4M | PFE, TEVA, NTRA, STVN, ARGX |
| Q2 2024 | 25 | $395.5M | TEVA, ARGX, ASND, AMGN, NTRA |
| Q1 2024 | 27 | $288.4M | TEVA, AVDL, SILK, NTRA, ASND |